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Edited by Judit Ova´diAbstract The juxtamembrane (JM) regions of several receptor
tyrosine kinases are involved in autoinhibitory interactions that
maintain the low basal activity of the receptors; mutations can
give rise to constitutive kinase activity and signaling. In this re-
port, we show that the JM region of the human insulin-like
growth factor I receptor (IGF1R) plays a role in kinase regula-
tion. We mutated JM residues that were conserved in this sub-
family of receptor tyrosine kinases, and expressed and puriﬁed
the cytoplasmic domains using the Sf9/baculovirus system. We
show that a kinase-proximal mutation (Y957F) and (to a lesser
extent) a mutation in the central part of the JM region
(N947A) increase the autophosphorylation activity of the kinase.
Steady-state kinetic measurements show the mutations cause an
increase in Vmax for phosphorylation of peptide substrates. When
the holoreceptors were expressed in ﬁbroblasts derived from
IGF1R-deﬁcient mice, the Y957F mutation led to a large in-
crease in basal and in IGF1-stimulated receptor autophosphory-
lation. Together, these data demonstrate that the JM region of
IGF1R plays an important role in limiting the basal activity of
the receptor.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The human insulin-like growth factor I receptor (IGF1R)
plays an important signaling role in many tissues and cell types
[1–3]. IGF1R, like the closely related insulin receptor (IR), is a
heterotetrameric receptor tyrosine kinase (RTK) consisting of
two extracellular a subunits and two transmembrane b sub-
units [4,5]. The kinase catalytic domains are in the cytoplasmic
regions of the b subunits. IGF1R is activated by binding of the
growth factor ligand IGF1 (or the lower-aﬃnity ligand IGF2)
to the extracellular domain of the receptor. Ligand binding
promotes a conformational change in the b subunits, which
stimulates the intrinsic tyrosine kinase activity of the receptor.
A key step in the activation process is the autophosphorylation
of three tyrosines in the activation loop, a ﬂexible segment
within the catalytic domain of the kinase [1,5–8]. The activated
IGF1R kinase phosphorylates cellular substrates such as IRS-*Corresponding author. Fax: +1 631 444 3432.
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doi:10.1016/j.febslet.2007.06.0141 and IRS-2, initiating a number of signaling pathways, includ-
ing the phosphatidylinositol 3-kinase (PI-3K)/Akt and Erk/
MAPK pathways.
Autoinhibitory interactions are present in RTKs to prevent
enzyme activation in the absence of ligand. For many RTKs,
autoregulatory regions lie outside the core kinase domain. The
C-terminal portion of the cytoplasmic domains of Tie2 [9,10],
ErbB2 [11], PDGF receptor [12], and RON [13] are involved
in enzyme regulation. For some RTKs, the juxtamembrane
(JM) regions (the portions of the cytoplasmic domains between
the transmembrane sequence and the kinase domains) clearly
play a negative regulatory role [14]. Tyrosine residues in the
JM region of several RTKs function as direct inhibitors of cat-
alytic function, and also serve as recruitment sites for various
downstream signaling proteins. These include EphB2 [15],
FLT3 (FMS-like tyrosine kinase 3) [16], MuSK [17], and c-Kit
[18]. The crystal structures of the autoinhibited forms of these
kinases have been solved, and they demonstrate the structural
basis for the negative regulatory role of the JM region in RTKs.
The JM regions of these RTKs prevent the activation loop from
adopting an active conformation, and phosphorylation within
the JM region relieves autoinhibition. Mutations in the JM re-
gion of c-Kit that give rise to gastrointestinal stromal tumors
are predicted to disrupt the autoinhibitory interactions [19].
The juxtamembrane region of IR consists of 35 amino acids
and has also been implicated in the control of kinase activity.
There are two autophosphorylation sites (Y965 and Y972)
within the JM region of IR. In contrast to the RTKs listed
above, autophosphorylation at these sites in IR does not ap-
pear to aﬀect kinase activity, so autoinhibition is not controlled
by phosphorylation in the case of IR [14]. The JM region of IR
contains another tyrosine (Y984) which is not a site of auto-
phosphorylation, but which has been shown to be important
for autoinhibition. A Y984A mutation increases IR kinase
activity in vitro and IR activity in cellular assays [20]. The
three-dimensional structure of a portion of the IR JM-kinase
domain shows that unphosphorylated Y984 interacts with res-
idues in the N-terminal lobe of the kinase domain [20]. This ap-
pears to prevent the catalytically important helix aC from
pivoting inwards to adopt its productive conformation.
The JM region of IGF1R is 65% conserved with IR; tyro-
sines 972 and 984 are present in IGF1R (IGF1R numbering:
Y950 and Y957). There is also a 5-residue deletion in the
IGF1R JM region relative to IR (Fig. 1). In this study, we car-
ried out experiments to determine whether the juxtamembrane
region of IGF1R plays a role in regulating kinase activity. We
demonstrate that a Y957F mutant, and to a lesser extent an
N947A mutant, have higher activity than wild-type IGF1Rblished by Elsevier B.V. All rights reserved.
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Fig. 1. The juxtamembrane sequences of insulin receptor (IR) and IGF1 receptor (IGF1R). Adapted from [14]. Residues shaded yellow are identical
in IR and IGF1R; residues in boldface are conserved across the entire IR/IGF1R subfamily and in all species. Dashes represent deletions. Residues
marked with an asterisk were targeted for mutagenesis in this study.
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proximal juxtamembrane region has an autoinhibitory role.2. Materials and methods
2.1. Expression and puriﬁcation of IGF1R cytoplasmic domain
PCR was used to amplify sequences encoding residues 930–1337 of
human insulin like growth receptor (IGF1R). This includes the juxta-
membrane (JM) region of the receptor, the kinase domain, and the C-
terminal tail. The IGF1R DNA was then subcloned as a BamHI–KpnI
fragment into plasmid pFastBac HTb (Life Technologies, Inc). Site-di-
rected mutagenesis was performed using the Stratagene QuikChange
kit according to the manufacturer’s directions. Mutations were con-
ﬁrmed by DNA sequencing. Recombinant baculovirus was produced
using the Bac-to-Bac system (Life Technologies, Inc.), and this was
used to infect Spodoptera frugiperda (Sf9) cells.
For protein production, 600 ml of Sf9 cells were infected with high-
titer recombinant IGF1R baculovirus. Cells were harvested after 72 h,
at which point maximum IGF1R expression was observed. Cells were
lysed in a French pressure cell in a lysis buﬀer containing 50 mM Tris–
HCl (pH 8.5), 5 mM b-mercaptoethanol, 5 mM EDTA, 1% Triton X-
100, 5 lg/ml aprotinin, 5 lg/ml leupeptin, 2 mM PMSF, and 2 mM
activated sodium orthovanadate. The lysate was then loaded onto a
5 ml column of Ni-NTA resin (Qiagen) that had been pre-equilibrated
in buﬀer A (20 mM Tris–HCl, pH 8.5, 500 mM KCl, 20 mM imidaz-
ole, 5 mM 2-mercaptoethanol, 10% v/v glycerol). The column was
washed with 10 column volumes of buﬀer A, followed by 2 column vol-
umes of buﬀer B (20 mM Tris–HCl, pH 8.5, 1 M KCl, 5 mM 2-
mercaptoethanol, 10% v/v glycerol), then an additional 5 column
volumes of buﬀer A. IGF1R cytoplasmic domain was eluted with buf-
fer C (20 mM Tris–HCl, pH 8.5, 100 mM KCl, 100 mM imidazole,
5 mM 2-mercaptoethanol, 10% v/v glycerol). Fractions containing
IGF1R were pooled and stored in aliquots at 80 C in 40% glycerol.
2.2. Kinetic experiments
The puriﬁed proteins were analyzed using a continuous spectropho-
tometric assay [21,22]. All experiments were carried out at 30 C in
50 ll of buﬀer containing 100 mM Tris–HCl (pH 7.5), 10 mM MgCl2,
1.5 mM phosphoenolpyruvate, 201 U/ml pyruvate kinase, 230 U/ml
lactate dehydrogenase, and 0.5 mM NADH. Initial rates were mea-
sured, and kinetic parameters were determined by non-linear regres-
sion analysis of the rates using the program MacCurveFit.
For determining values of Km for peptide or ATP substrate with
phosphorylated IGF1R, enzyme was phosphorylated with 5 mM
ATP for 10 min at room temperature prior to being used in the spec-
trophotometric assay. For determinations of Km for peptide, the syn-
thetic peptide KKEEEEYMMMMG (E4YM4) was used in
concentrations of 0–4000 lM. The concentration of ATP in these as-
says was 1 mM and the concentration of the phosphorylated proteins
was 200 nM. For determinations of Km for ATP, the peptide concen-
tration was 1 mM, the enzyme concentration was 100 nM, and the con-
centrations of ATP were 0–6000 lM. Kinetic parameters were
calculated by ﬁtting data to the Michaelis–Menten equation.
For kinetic measurements with dephosphorylated IGF1R, proteins
(2 lM) were treated with glutathione-agarose containing GST-YOP
for 30 min at room temperature. This treatment was suﬃcient to com-
pletely dephosphorylate the receptors, as detected by anti-pTyr Wes-tern blotting (data not shown). The GST-YOP was then inactivated
for 5 min with sodium orthovanadate. The beads were removed by
centrifugation, and IGF1R was used in the spectrophotometric assay
at a concentration of 200 nM. Initial studies on dephosphorylated
wild-type and mutant forms of IGF1R with varying concentrations
of peptide E4YM4 established that the Michaelis constants were in
the millimolar range (2 mM). Thus, it was not possible to determine
accurate Michaelis constants by using initial rate kinetics. The com-
plete time course for the phosphorylation of peptide was measured
by using peptide concentrations less than the Michaelis constant. We
analyzed the data graphically as described [23] to determine kcat/Km.
To analyze IGF1R autophosphorylation by Western blotting, the
proteins were ﬁrst dephosphorylated as described above. After removal
of GST-YOP, the remaining solution was incubated with 100 mM Tris
(pH 7.5), 19 mM MgCl2, and 250 lM ATP in a total volume of 50 ll.
Aliquots containing 100 ng protein were removed at various time points
and analyzed by 7.5% SDS–PAGE. Proteins were transferred onto
PVDF membranes and probed with rabbit polyclonal anti-IGF1R
[pYpY1135/1136] antibody (Biosource International, Inc.), followed
by horseradish peroxidase-conjugated goat anti-rabbit antibody (GE
Healthcare). Detection was by ECL Western Blot Detection System
(GE Healthcare). All blots were exposed together to a single piece of
Kodak MR ﬁlm to compare time courses of autophosphorylation. To
analyze the stoichiometry of autophosphorylation, IGF1R proteins
(2 lM) were incubated with 250 lM [c-32P]-ATP for 15 min under sim-
ilar conditions. The reactionswere stopped bymixingwithLaemmli Buf-
fer and boiling, and analyzed by SDS–PAGE followed by staining with
Coomassie blue. Bands were excised from the gel and dissolved in H2O2,
and 32P incorporation was measured using a liquid scintillation counter.
2.3. Receptor activity in R-cells
Wild-type and mutant forms of IGF1R were expressed using plas-
mid pBPV.IGF1R (a gift of Dr. Derek LeRoith, NIH). R-cells (a gift
of Dr. Renato Baserga, Thomas Jeﬀerson University) were grown to
50% conﬂuency in DMEM plus 4500 mg/l glucose (Fisher/Cellgro),
10% heat inactivated fetal bovine serum (Sigma), 1X antibiotic/antimy-
cotic (Gibco/Invitrogen), 50 lg/ml G418(Sigma). R-cells were transfec-
ted using TransIT polyamine transfection reagent (Mirus) according to
the manufacturer’s instructions. After 24 h, the media was replaced
with starvation media containing DMEM plus 1000 mg/l glucose, 1X
antibiotic/antimycotic, 50 lg/ml G418, 0.5% BSA, and 50 lg/ml holo-
transferrin (Sigma). After 16 h in starvation media, cells were stimu-
lated with 40 ng/ml IGF1 (Calbiochem) for 10 min at 37 C or were
left unstimulated. Cells were lysed in 1 ml lysis buﬀer containing
25 mM Tris–HCl (pH 8), 2 mM EDTA, 140 mM NaCl, 1% NP40,
1 lg/ml aprotinin, 1 lg/ml leupeptin, and 2 mM activated sodium
orthovanadate. The lysates were clariﬁed and the protein concentra-
tions adjusted to 2 mg/ml with lysis buﬀer. For immunoprecipitation,
anti-IGF1R antibody (2 lg of anti-IGF1R clone JBW902, Millipore)
was added to each lysate for 1 h at 4 C. Protein A-conjugated agarose
beads (Sigma) (60 ll) were added to each tube and incubated at 4 C
for 3 h with gentle rocking. The beads were collected and washed with
lysis buﬀer ﬁve times. The precipitated proteins were analyzed on 7.5%
SDS–polyacrylamide gels and transferred to PVDF membrane (Milli-
pore). Blots were probed with anti-IGF1R [pYpY1135/1136] antibody,
and visualized with the SuperSignal West Femto Maximum Sensitivity
substrate system (Pierce). The blots were then stripped and reprobed
with anti-IGF1R antibody. Densitometry was performed with Odyssey
analysis software, version 2.1 (LI-COR Biosciences).
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Fig. 3. Autophosphorylation of the puriﬁed IGF1R cytoplasmic
domains. The proteins were ﬁrst completely dephosphorylated by
treatment with GST-YOP. After removal of GST-YOP, the proteins
were incubated with ATP and MgCl2. Aliquots (containing 100 ng
protein) were removed at various time points and analyzed by SDS–
PAGE with anti-pY1135/pY1136 Western blotting.
B.P. Craddock et al. / FEBS Letters 581 (2007) 3235–3240 32373. Results
3.1. Mutagenesis of IGF1R juxtamembrane region
As shown in Fig. 1, there is signiﬁcant homology between
the juxtamembrane regions of IR and IGF1R, although the
N-terminal portions are divergent and there is a 5-residue
gap in IGF1R relative to IR. Of the residues that are conserved
between the two receptors, four (N947, Y950, Y957, and
D960; IGF1R numbering) are conserved across the entire
IR/IGF1R family and in all species [14]. In IR, the residues
corresponding to IGF1R Y943 and Y950 are sites of auto-
phosphorylation; however, phosphorylation at these sites does
not regulate kinase activity. The IR residue corresponding to
Y943 is involved in receptor endocytosis [24], while the IR res-
idue corresponding to Y950 is a docking site for IRS proteins
[25], Shc [26], and STAT-5b [27]. A structure of IR has been
solved that contains a portion of the JM region [20]. In the
structure, residues in the C-terminal half of the JM region of
IR (equivalent to V956, Y957, V958, D960, W962, E963 of
IGF1R) participate in interactions that could stabilize the
autoinhibited state. The N-terminal half of the JM region
was not included in the structural study and has not been ex-
plored in IR or IGF1R. There is also biochemical evidence
for an autoinhibitory role for Tyr984 in IR (equivalent to
Y957 of IGF1R) [20]. To probe the roles of the conserved res-
idues, we produced the following site-directed mutants of
IGF1R: N947A, Y950F, and Y957F. To study these mutations
in the context of the entire cytoplasmic domain, we used the
Sf9/baculovirus system to express His-tagged versions of
IGF1R containing the juxtamembrane, kinase, and C-terminal
domains. To our knowledge, this is the ﬁrst report on the
expression and puriﬁcation of a full cytoplasmic domain from
an IGF1R/IR-family kinase. We puriﬁed the wild-type and
mutant proteins to near-homogeneity using aﬃnity chroma-
tography (Fig. 2).
3.2. Autophosphorylation of wild-type and mutant IGF1R
As an initial comparison of the activity of the wild-type and
mutant receptors, we carried out in vitro autophosphorylation
reactions. To ensure that all proteins began the reaction in an
equivalent, unphosphorylated state after puriﬁcation, we trea-
ted the puriﬁed proteins with Yersinia YOP tyrosine phospha-
tase. After removal of the phosphatase, we incubated the
enzymes with ATP and followed the autophosphorylationWT N9
47
A
Y9
50
F
Y9
57
F
31
45
66
97
116
200
Fig. 2. The puriﬁed cytoplasmic domains of wild-type and mutant
forms of IGF1R, comprising the juxtamembrane, kinase, and
C-terminal domains. Proteins were visualized by SDS–PAGE with
Coomassie blue staining.reactions using a phosphospeciﬁc antibody that recognizes
pY1135 and pY1136 in the IGF1R activation loop (Fig. 3).
These experiments conﬁrmed that all four proteins were capa-
ble of in vitro autophosphorylation under the conditions
tested. The Y957F mutant showed a more rapid and robust
signal for autophosphorylation than wild-type IGF1R or the
other mutants (Fig. 3).
To conﬁrm these results, we carried out experiments using a
continuous spectrophotometric assay (Fig. 4). In this assay,
the production of ADP is coupled to the oxidation of NADH,
which is measured as a reduction in absorbance at 340 nm. The
enzymes were incubated with ATP in the absence of any exog-
enous substrate. As we observed previously for the isolated
catalytic domain of IGF1R [6], the progress curves were bipha-
sic, because autophosphorylation activates IGF1R. Autophos-
phorylation of the Y957F and N947A mutants was more rapid
than for wild-type IGF1R (Fig. 4). Autophosphorylation of
the Y950F mutant was slower than for wild-type. We mea-
sured the stoichiometry of autophosphorylation after 15 min
of reaction under similar conditions using 32P-labeled ATP.
Wild-type IGF1R incorporated 1.5 mol phosphate per mol
protein in this experiment, while the N947A mutant incorpo-
rated 1.8 mol/mol, Y950F incorporated 1.3 mol/mol, and
Y957F incorporated 2.5 mol/mol, consistent with the results
from the spectrophotometric assay.
3.3. Kinetic experiments
To test whether the activating eﬀects of the Y957F and
N947A mutations would also be manifested towards an exog-
enous substrate, we carried out steady-state kinetic experi-
ments using receptors that were pre-phosphorylated by ATP.
In these studies, we measured phosphorylation of a synthetic
peptide substrate using the continuous spectrophotometric as-
say (Fig. 5). In experiments where the concentration of ATP or
peptide was varied, the N947A and Y957F mutants showed
higher activity than wild-type, and the Y950F mutant showed
lower activity. These diﬀerences were primarily due to changes
in Vmax between the mutants and wild-type; only modest eﬀects
were seen on the values of Km for ATP and peptide (Table 1).
The values of Vmax for N947A and Y957F were approximately
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Fig. 5. Kinetic experiments with autophosphorylated IGF1R cyto-
plasmic domains. Wild-type and mutant proteins were pre-phosphor-
ylated as described in Section 2. The continuous spectrophotometric
assay was used to measure phosphorylation of the synthetic peptide
E4YM4. Data were ﬁt to the Michaelis–Menten equation. Open
squares, N947A; closed circles, Y957F; open circles, wild-type IGF1R;
closed squares, Y950F. (A) Experiments with varying concentrations
of ATP. (B) Experiments with varying concentrations of peptide.
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Fig. 4. Autophosphorylation activity of the wild-type and JM mutant IGF1R cytoplasmic domains. Enzymes (2 lM) were incubated with 1 mM
ATP, and autophosphorylation was measured using the continuous spectrophotometric assay. Data were recorded every 6 s.
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was approximately twofold lower than wild-type.
We also analyzed the kinetics of the unphosphorylated ki-
nases. We treated the preparations with YOP phosphatase;
preliminary experiments conﬁrmed that these conditions were
suﬃcient to completely dephosphorylate the enzymes (datanot shown). After removal of YOP, we carried out kinetic
experiments using the continuous spectrophotometric assay.
As reported previously for the isolated kinase domain of
IGF1R [6], the Michaelis constants for peptide and for ATP
were much higher for dephosphorylated IGF1R than for phos-
phorylated IGF1R. Because we were unable to achieve sub-
strate saturation in these experiments, we determined kcat/Km
values from complete enzyme progress curves [23] (Table 2).
As expected, these values were 300-fold lower than the kcat/
Km values for autophosphorylated enzyme (Table 1). These
experiments showed that the Y957F mutant had a 3-fold
higher kcat/Km than wild-type IGF1R, whereas the change
for N947A was not signiﬁcant (Table 2).
3.4. Receptor activity in intact cells
We carried out experiments to test the eﬀects of the juxta-
membrane mutations in the context of the full-length IGF1R.
We conducted these experiments in R-cells, which are murine
ﬁbroblasts derived from IGF1R-deﬁcient mice. We transfected
R-cells with wild-type, Y950F, N947A, or Y957F IGF1R,
starved the cells, then treated them with IGF1. We assayed
receptor autophosphorylation by immunoprecipitation and
Western blotting with anti-pY1135/pY1136 antibodies
(Fig. 6). Both the wild-type and mutant receptors were acti-
vated by IGF1 treatment, indicating that the mutations did
not disrupt the overall structure of the receptor. The Y957F
juxtamembrane mutation resulted in a dramatic increase in
both the basal and IGF1-stimulated levels of receptor auto-
phosphorylation. The N947A mutation also increased the ba-
sal and IGF1-stimulated level of autophosphorylation, but not
as strongly as Y957F. The Y950F mutation resulted in a low
level of autophosphorylation in the absence of IGF1, and
IGF1 treatment stimulated autophosphorylation to approxi-
mately the same degree as wild-type IGF1R. These data dem-
onstrate that Y957 and N947 participate in autoinhibitory
interactions in the context of the full-length IGF1receptor.4. Discussion
In this report, we present evidence that the juxtamembrane
region of IGF1R plays a role in regulating the activity of the
enzyme. Our in vitro and cellular data point to a particularly
Table 1
Kinetic parameters for phosphorylation of peptide substrate by the autophosphorylated wild-type (WT) and mutant forms of IGFIR
Enzyme Km, peptide (lM) Km, ATP (lM) Vmax (lmol min
1 mg1) kcat/Km (s
1 lM1)
WT 760 ± 70 390 ± 40 1.9 ± 0.1 10.8
N947A 540 ± 80 270 ± 40 4.2 ± 0.14 27.0
Y950F 500 ± 100 270 ± 30 0.8 ± 0.03 10.2
Y957F 530 ± 40 640 ± 100 3.7 ± 0.22 23.4
Table 2
Kinetic parameters for phosphorylation of peptide substrate by the
unphosphorylated wild-type (WT) and mutant forms of IGFIR
Enzyme kcat/Km (s
1 lM1)
WT 3.2 · 102
N947A 3.8 · 102
Y950F 2.8 · 102
Y957F 10.2 · 102
WT Y957F N947A Y950F
IGF1: -     +      -      +      -      +      -      +
IP: IGF1R
blot: pY1135/pY1136
IP: IGF1R
blot: IGF1R
0.03 1.0 2.7 8.4 0.8 4.2 1.1 1.6
Fig. 6. Autophosphorylation activity of wild-type and mutant holo-
receptors. IGF1R-deﬁcient cells were transfected with WT IGF1R or
the JM mutants. After overnight starvation, cells were treated with or
without IGF1 for 10 min. Top panel: IGF1R was immunoprecipitated
and analyzed by anti-pY1135/pY1136 Western blotting. Densitometric
analysis was performed on the anti-pY1135/pY1136 Western blot, and
values are given below the blot (normalized to 1.0 for IGF1-treated
wild-type IGF1R). Bottom panel: the membrane was stripped and
reprobed with anti-IGF1R antibody. This experiment was repeated
four times with similar results.
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gion proximal to the kinase catalytic domain. Our data also
suggest a role for N947 in IGF1R regulation. The eﬀects of
the Y957F and N947A mutations were much more dramatic
in cellular studies with the full-length receptor (Fig. 6) than
in the in vitro studies on puriﬁed cytoplasmic domains (Figs.
3–5). A similar discrepancy was observed for the Y984F mu-
tant form of IR [20]. This discrepancy is probably due to the
additional steric constraints imposed on the cytoplasmic do-
main when it is assembled into the complete a2b2 holoreceptor.
For this reason, it is likely that the studies in R-cells (Fig. 6)
show more accurately the level to which the JM region is in-
volved in regulating IGF1R activity. In the case of the
Y950F mutant, our in vitro experiments showed no evidence
for the involvement of Y950 in IGF1R regulation. The cellular
data showed a modest degree of basal autophosphorylation for
the Y950F mutant, and a normal level of IGF1-stimulated
autophosphorylation, as has been reported previously [28].
In previous studies of IR regulation, biochemical and struc-
tural studies on Y984 (the equivalent tyrosine to Y957 of
IGF1R) showed that the residue was engaged in autoinhibi-
tory interactions with the kinase catalytic domain [20]. Y984
of IR is not a site of autophosphorylation, and there is no evi-
dence that Y957 of IGF1R is autophosphorylated. Thus,trans-autophosphorylation is not believed to play a role in
JM-mediated autoinhibition in this enzyme family. The crystal
structure of a JM-catalytic construct showed that Y984 inter-
acts with residues in the N-terminal lobe of the catalytic
domain to stabilize a low-activity conformation. Kinetic
measurements showed that a Y984A mutant had a fourfold
higher kcat than wild-type insulin receptor, and the Y984A
mutation increased IR phosphorylation in cells. The increase
in basal-state phosphorylation for the Y984 mutant suggested
that juxtamembrane region interactions are important for
maintaining an arrangement of the two receptor catalytic do-
mains with low trans-autophosphorylation activity. This
arrangement is disrupted upon insulin binding to the extracel-
lular alpha subunits.
The autoinhibitory role for Y957 of IGF1R is supported by
the available structural data. Crystal structures of IGF1R have
been described in the unphosphorylated (0P), bis-phosphory-
lated (2P), and triply-phosphorylated (3P) states [6,29,30]. In
the IGF1R-0P and -2P structures, Y957 makes similar con-
tacts with hydrophobic residues in the N-terminal lobe of the
catalytic domain as seen in the IR juxtamembrane-catalytic
structure. As noted previously by Li et al. [20], there is a subtle
repositioning of the Y957 sidechain in IGF1R relative to the
sidechain of Y984 in IR. Y957 of IGF1R is hydrogen-bonded
to K1025 in the N-lobe, whereas Y984 of IR is hydrogen-
bonded to E990. Despite this diﬀerence, the similarities in
the biochemical data for the two mutant proteins (IR Y984A
and IGF1R Y957F) suggest that these residues play a funda-
mentally similar role in the two receptors. The similar roles
of IR Y984 and IGF1R Y957 suggest that the two residues
might also participate in autoinhibitory interactions in the con-
text of IR/IGF1R hybrid receptors, although this possibility
has not yet been investigated. In the structures of the triply-
phosphorylated forms of IR [31] and IGF1R [6], the juxta-
membrane regions containing Y984/Y957 are disengaged from
the kinase catalytic domain, consistent with the high catalytic
activity seen in these forms of the receptors.
The juxtamembrane region amino acids beginning at N947
were resolved in a crystal structure of a mutant form of
IGF1R-0P [32]. In this structure, N947 and Y950 are in a por-
tion of the juxtamembrane region that extends away from the
amino-terminal lobe of the kinase domain. Two molecules of
IGF1R-0P were observed in the asymmetric unit associated
as a dimer in two possible ways: one with the active sites facing
each other, and one with the active sites pointed away from
each other. In the dimer with active sites pointed inward, it
is conceivable that the amino-terminal portion of the juxta-
membrane region in this construct (beginning at N947) could
inﬂuence the catalytic activity of the opposing monomer. On
the other hand, in solution, IGF1R kinase domain is known
to act as a monomer. Thus, the structural basis for the in-
creased activity of the N947A mutant of IGF1R is not obvious
from the available data. Nonetheless, our results show that the
3240 B.P. Craddock et al. / FEBS Letters 581 (2007) 3235–3240autoinhibitory sequences in the JM region of IGF1R include
Y957, but also extend distally from the catalytic domain to-
wards the membrane. Broadly speaking, the data show that
additional constraints exist (apart from the triple phosphoryla-
tion of the activation loop) that limit the basal enzyme activity
of this receptor.
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